Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: Oxaliplatin-based adjuvant chemotherapy in patients with stage III colon cancer (CC) for 6 months remains a standard in high-risk stage III patients. Data are lacking as to whether early discontinuation of all treatment (ETD) or early discontinuation of oxaliplatin (EOD) could worsen the prognosis.
Materials And Methods: We studied the prognostic impact of ETD and EOD in patients with stage III CC from the ACCENT/IDEA databases, where patients were planned to receive 6 months of infusional fluorouracil, leucovorin, and oxaliplatin or capecitabine plus oxaliplatin. ETD was defined as discontinuation of treatment and EOD as discontinuation of oxaliplatin only before patients had received a maximum of 75% of planned cycles. Association between ETD/EOD and overall survival and disease-free survival (DFS) were assessed by Cox models adjusted for established prognostic factors.
Results: Analysis of ETD and EOD included 10,447 (20.9% with ETD) and 7,243 (18.8% with EOD) patients, respectively. Compared with patients without ETD or EOD, patients with ETD or EOD were statistically more likely to be women, with Eastern Cooperative Oncology Group performance status ≥ 1, and for ETD, older with a lower body mass index. In multivariable analyses, ETD was associated with a decrease in disease-free survival and overall survival (hazard ratio [HR], 1.61, < .001 and HR, 1.73, < .001), which was not the case for EOD (HR, 1.07, = .3 and HR, 1.13, = .1). However, patients who received < 50% of the planned cycles of oxaliplatin had poorer outcomes.
Conclusion: In patients treated with 6 months of oxaliplatin-based chemotherapy for stage III CC, ETD was associated with poorer oncologic outcomes. However, this was not the case for EOD. These data favor discontinuing oxaliplatin while continuing fluoropyrimidine in individuals with significant neurotoxicity having received > 50% of the planned 6-month chemotherapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1200/JCO.21.02726 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Digital Cueing With Laser Shoes Does Not Improve Walking in Parkinson's Disease: Evidence Across Disease Severity and Freezing Status.
Neurorehabil Neural Repair
September 2025
Department of Sport, Exercise and Rehabilitation, Northumbria University, Newcastle upon Tyne, UK.
Background: Gait impairment in Parkinson's disease (PD) occurs early and pharmaceutical interventions do not fully restore this function. Visual cueing has been shown to improve gait and alleviate freezing of gait (FOG) in PD. Technological development of digital laser shoe visual cues now allows for visual cues to be used continuously when walking.
View Article and Find Full Text PDFComparative analysis of Birmingham hip resurfacing: Minimum 2-year follow-up clinical outcomes in obese vs. non-obese populations.
J Orthop Sci
September 2025
American Hip Institute Research Foundation, Chicago, IL 60018, USA; American Hip Institute, Chicago, IL 60018, USA. Electronic address:
Background And Objective: With obese individuals experiencing osteoarthritis (OA) at early stages of life, hip resurfacing (HR) has emerged as an alternative to arthroplasty. The purpose is to conduct a short-term analysis on patients with obesity who underwent primary HR for OA compared to a benchmark control group of non-obese patients.
Materials And Methods: Patients with a body mass index (BMI) ≥ 30 kg/m2 who underwent HR from 2010 to 2021 were eligible for inclusion.
A National Cancer Database analysis of the clinicopathologic characteristics and outcomes of appendiceal neuroendocrine tumors.
Surgery
September 2025
Ellen Leifer Shulman and Steven Shulman Digestive Disease Center, Cleveland Clinic Florida, Weston, FL. Electronic address:
Introduction: Appendiceal neuroendocrine neoplasms are rare lesions which are generally incidentally discovered during or after appendectomies. Recent advances have refined their classification and improved diagnostic rates, highlighting their distinct pathologic and clinical presentations. The present study aimed to assess the characteristics and outcomes of appendiceal neuroendocrine neoplasms using data from the U.
View Article and Find Full Text PDFHuman papillomavirus: problems and prospects for women's reproductive health (systematic review).
Pol Merkur Lekarski
September 2025
LLC "ECOFARM", KYIV, UKRAINE.
Objective: Aim: To consider the specific activity of drops and suppositories of PROTEFLAZID® at the stage of preclinical study, to assess the effectiveness and safety of use in clinical practice in papillomavirus-associated diseases of the female reproductive system..
Patients And Methods: Materials and Methods: Analysis of scientific publications on the treatment of palilomavirus infection with PROTEFLAZID® in women over the past decade.
Sociodemographic and clinical factors associated with delayed diagnosis of cervical cancer: a cross-sectional study, Brazil, 2016-2020.
Epidemiol Serv Saude
September 2025
Universidade Federal do Rio Grande do Norte, Natal, RN, Brazil.
Objectives: To assess the time taken to diagnose cervical cancer in Brazil and identify associated sociodemographic and clinical factors in the period 2016-2020.
Methods: This was a cross-sectional study of cervical neoplasms diagnosed between 2016 and 2020, using data collected from the Hospital Cancer Registry. The logistic regression model was applied to calculate odds ratios (OR) and 95% confidence intervals (95%CI).